Drug intelligence / Profile preview

Beriplast

Development stage
Unknown
Lead developer
CSL Behring
Modality
Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

Beriplast is a topical fibrin sealant and tissue adhesive derived from human plasma, primarily used for hemostasis, tissue sealing, and wound healing across various surgical specialties. Developed by **CSL Behring**, it consists of two primary components that mimic the final stage of the blood coagulation cascade: a fibrinogen concentrate (containing fibrinogen and Coagulation Factor XIII) and a thrombin solution (containing human thrombin and calcium chloride). When these components are mixed upon application, thrombin catalyzes the conversion of fibrinogen into fibrin monomers, which polymerize to form a clot. Coagulation Factor XIII, activated by thrombin in the presence of calcium, then cross-links the fibrin strands to create a stable, insoluble, and adhesive matrix. Many formulations also include aprotinin, a bovine-derived protease inhibitor, to delay the premature degradation of the fibrin clot by plasmin (fibrinolysis).

Brand names
BeriplastBeriplast PBeriplast P Combi-Set
Other names
Fibrin sealantFibrin glueFibrin tissue adhesiveExogenous liquid fibrin glue
02

Targets

F2 (Thrombin)PLG (Plasminogen)FXIIIa (Coagulation factor XIII A subunit)

Beyond the preview

Go deeper on Beriplast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beriplast.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call